BioMed Research International

BioMed Research International / 2019 / Article

Corrigendum | Open Access

Volume 2019 |Article ID 9406241 | 1 page | https://doi.org/10.1155/2019/9406241

Corrigendum to “Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury”

Received16 Jul 2019
Accepted16 Jul 2019
Published22 Aug 2019

Following publication of the article, “Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury” [1], the authors were made aware that the effects of epalrestat on the high glucose-mediated modulation of Akt and ERK pathways were not clear due to the experimental setup.

An additional experiment was completed to confirm that the exposure of NRK-52E cells to 30 mM high glucose (HG) caused a prominent reduction in the phosphorylation of Akt (about 60% as compared to the control), which was prevented in cells coincubated with epalrestat (EPS; 1 μM) during high glucose exposure. In addition to the original data shown in Figure 2, this suggests that high glucose conditions acutely activate Akt signalling (within 10 minutes of exposure to high glucose) in renal tubular cells whereas sustained exposure to high glucose decreases Akt activation, which could eventually contribute to tubular cell death.

Additionally, the published article incorrectly states that “AR inhibition exerts a protective effect on kidney cells through attenuation of Akt and ERK-dependent pathways” in Discussion. Please read the corrected statement as follows:

Furthermore, the diminished Akt activity in NRK-52E cells following 48 hours of high glucose exposure (Supplemental Figure 1) corroborates with the loss of cell viability in these cells (Figure 1). Interestingly, cotreatment with epalrestat prevented not only the high glucose-induced loss of cell viability but also the diminution of Akt activity in NRK-52E cells.

Supplementary Materials

Supplemental Figure 1: NRK-52E cells were exposed to high glucose (HG) with and without epalrestat (EPS; 1 μM) for 48 hours and assessed for its effect on Akt pathway. (a) A representative western blot showing the expression of p-Akt and total Akt. (b) Bar graph showing densitometry data of p-Akt expression normalized to total Akt expression. (Supplementary Materials)

References

  1. H. El Gamal, A. H. Eid, and S. Munusamy, “Renoprotective effects of aldose reductase inhibitor epalrestat against high glucose-induced cellular injury,” BioMed Research International, vol. 2017, Article ID 5903105, 11 pages, 2017. View at: Publisher Site | Google Scholar

Copyright © 2019 Heba El Gamal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

437 Views | 191 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.